62
50. Coppola N, De Pascalis S, Onorato L, Calo F, Sagnelli C, Sagnelli E.
Hepatitis B virus and hepatitis C virus infection in healthcare workers.
World J Hepatol. 2016;8(5):273–81.
51. Westermann C, Peters C, Lisiak B, Lamberti M, Nienhaus A. The prevalence
of hepatitis C among healthcare workers: a systematic review and meta-
analysis. Occup Environ Med. 2015;72(12):880–8.
52. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent
epidemic of acute hepatitis C virus in HIV-positive men who have sex with
men linked to high-risk sexual behaviours. AIDS. 2007;21(8):983–91.
53. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et
al. Sofosbuvir and velpatasvir for HCV in patients with decompensated
cirrhosis. N Engl J Med. 2015;373(27):2618–28.
54. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al.
Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N
Engl J Med. 2015;373(27):2599–607.
55. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al.
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J
Med. 2015;373(27):2608–17.
56. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, et al. Efficacy
and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C
virus infection receiving opioid substitution therapy: analysis of phase 3
ASTRAL trials. Clin Infect Dis. 2016;63(11):1479–81.
57. Wyles D, Brau N, Kottilil S, Daar ES, Ruane P, Workowski K, et al. Sofosbuvir
and velpatasvir for the treatment of hepatitis C virus in patients coinfected
with human immunodeficiency virus type 1: an open-label, phase 3 study.
Clin Infect Dis. 2017;65(1):6–12.
58. Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, et al. Glecaprevir plus
pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection
in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-
label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062–8.
59. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al.
Glecaprevir and pibrentasvir yield high response rates in patients with HCV
genotype 1–6 without cirrhosis. J Hepatol. 1990;11(2):263–71.